Neuronetics Brightens Outlook For Neuro Devices

Neuronetics Inc. forged a new specialty of sorts, the interventional psychiatrist. Unlike other interventional approaches, the externally applied NeuroStar delivers transcranial magnetic stimulation to the precise area of the brain responsible for intractable depression. The device is changing the lives of psychiatrists who launched “TMS” clinics, hoping to capture the early success, and potentially creating opportunities for medical devices designed to treat other brain-related disorders.

A medical device, on occasion, can spawn a new specialty. A clever engineer designs a device or implant small enough to be deployed by those skilled with a guidewire and catheter, enabling an interventionalist to reach an organ previously accessible only through surgery. Over the past decades, these advances have helped minimize the physical impact of treating a blocked artery, fractured vertebrae or a dangerous spot of cancer. Neuronetics Inc. is an unlikely contributor to this movement. The nine-year-old neurostimulation company created a device capable of safely reaching one of the most remote areas of the body – the brain. And, in doing so, the company created a new specialty of sorts, one that carries a somewhat contradictory tag – the interventional psychiatrist.

Unlike other interventional approaches, Neuronetics’ NeuroStar TMS Therapy System doesn’t require an entry incision to access its targeted organ. Instead,...

More from Business Strategy

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.